426 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
SNY Sanofi $43.75 $109.14B Downtrend
Article Searches
Top Research Reports for Pepsico, Walt Disney & Sanofi http://www.zacks.com/research-daily/211132/top-research-reports-for-pepsico-walt-disney-sanofi?cid=CS-ZC-FT-211132 Feb 05, 2019 - Top Research Reports for Pepsico, Walt Disney & Sanofi
Can Sanofi (SNY) Keep the Earnings Surprise Streak Alive? http://www.zacks.com/stock/news/352151/can-sanofi-sny-keep-the-earnings-surprise-streak-alive?cid=CS-ZC-FT-352151 Feb 05, 2019 - Sanofi (SNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sanofi's Myeloma Candidate Meets Goal in Phase III Study http://www.zacks.com/stock/news/352133/sanofis-myeloma-candidate-meets-goal-in-phase-iii-study?cid=CS-ZC-FT-352133 Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store? http://www.zacks.com/stock/news/351772/regeneron-regn-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-351772 Feb 04, 2019 - Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV http://www.zacks.com/stock/news/349786/pharma-stock-roundup-jnj-bmys-q4-earnings-study-failures-at-lly-abbv?cid=CS-ZC-FT-349786 Jan 25, 2019 - J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Top Ranked Income Stocks to Buy for January 25th http://www.zacks.com/commentary/208418/top-ranked-income-stocks-to-buy-for-january-25th?cid=CS-ZC-FT-208418 Jan 25, 2019 - Top Ranked Income Stocks to Buy for January 25th
Moderna's Hot New mRNA Technology Has Competition https://www.fool.com/investing/2019/01/24/modernas-hot-new-mrna-technology-has-competition.aspx?source=iedfolrf0000001 Jan 24, 2019 - They're largely flying under the radar of most investors.
Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids http://www.zacks.com/stock/news/349470/sanofis-sny-influenza-vaccine-gets-fda-approval-for-kids?cid=CS-ZC-FT-349470 Jan 24, 2019 - Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.
Top Ranked Income Stocks to Buy for January 23rd http://www.zacks.com/commentary/207518/top-ranked-income-stocks-to-buy-for-january-23rd?cid=CS-ZC-FT-207518 Jan 23, 2019 - Top Ranked Income Stocks to Buy for January 23rd
Merck's Partner Gets FDA Nod for Herceptin Biosimilar http://www.zacks.com/stock/news/348729/mercks-partner-gets-fda-nod-for-herceptin-biosimilar?cid=CS-ZC-FT-348729 Jan 21, 2019 - Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.

Pages: 123456789...43

<<<Page 4>